Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate personalised treatment for patients.
Lifebit has announced a partnership with Troper Wojcicki Philanthropies (TWP), which deploys philanthropy and mission-related investments in key priority areas including accelerating cancer research.
Cancer Research Horizons has joined Lifebit’s Federated Data Network to help maximise the impact of data generated through Cancer Research UK-funded research.
Dr. James McCracken, senior commercial product manager at Beckman Coulter Life Sciences, discusses how cell sorting is a popular and growing use of flow cytometry – and one that many researchers rely on specialists to perform.
Enhanc3D Genomics, an innovator in 3D genomics technology, has announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug discovery.
23andMe Holding has announced the launch of Discover23, a new research offering enabling authorised collaborators to securely access to the power and diversity of the 23andMe research cohort.
To help potential customers streamline the critical toxicology process, Broughton, a toxicology specialist and regulatory consultancy, has summarised how ToxHQ, Broughton’s data-driven toxicology platform, supports product development.
AMSBIO has implemented a program of investment to support the students at Penn State Lehigh Valley, part of Pennsylvania State University, in their transformative Course-based Undergraduate Research Experience (CURE) program.
Without aligned process improvements across Regulatory Affairs, Quality and Pharmacovigilance/Drug Safety, pharma companies risk limiting their overall market performance, says MAIN5’s Tobias Hitziger.
